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ABSTRACT 
Bivalent chromatin domains containing both active H3K4me3 and repressive H3K27me3 
histone marks define gene sets poised for expression or silencing in differentiating 
embryonic stem (ES) cells. In cancer cells aberrantly poised genes may facilitate changes in 
transcriptional states after exposure to anti-cancer drugs. In this study, we used ChIP-seq to 
characterize genome-wide positioning of H3K4me3 and H3K27me3-associated chromatin in 
primary high-grade serous ovarian carcinomas and in normal ovarian surface and fallopian 
tube tissue. Gene sets with proximal bivalent marks defined in this manner were evaluated 
subsequently as signatures of systematic change in DNA methylation and gene expression, 
comparing pairs of tissue samples taken from patients at primary presentation and relapse 
following chemotherapy. We found that gene sets harboring bivalent chromatin domains at 
their promoters in tumor tissue, but not normal epithelia, overlapped with Polycomb-
repressive complex target genes as well as transcriptionally silenced genes in normal 
ovarian and tubal stem cells. The bivalently marked genes we identified in tumors before 
chemotherapy displayed increased promoter CpG methylation and reduced gene expression 
at relapse after chemotherapy of ovarian cancer. Overall, our results support the hypothesis 
that pre-existing histone modifications at genes in a poised chromatin state may lead to 
epigenetic silencing during acquired drug resistance. 
 
Precis: Results suggest epigenetic targets for intervention to prevent the emergence of 
cancer drug resistance. 
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INTRODUCTION 
 
Genetic information is packaged into human cells in the form of chromatin: double-stranded 
molecules of DNA wrapped around complexes of histone proteins. Covalent modifications of 
the histone tails can alter the density of compaction of chromatin, which can influence the 
accessibility of DNA to the transcription machinery that is required for gene expression. The 
Polycomb repressive complex (PRC2), suppresses target gene expression through 
catalysing the trimethylation of Lysine 27 of the histone protein H3 (H3K27me3)(1). This 
modified histone forms broad domains that are enriched at repressed genes(2). PRC2-null 
mouse Embryonic Stem (ES) cells can be derived, but do not contribute to viable organisms, 
so it is widely accepted that PRC2 and H3K27me3 play an important role in the 
differentiation of pluripotent cells. In ES cells, genomic loci bound by the core PRC2 
members (SUZ12, EED and EZH2) tend to display both the repressive mark H3K27me3 and 
permissive mark H3K4me3 (trimethylation of Lysine 4 of the histone protein H3). These 
'bivalent' promoters, simultaneously containing both active and repressive histone marks, 
are strongly enriched for genes whose expression either rapidly increases or rapidly 
decreases upon differentiation from ES cells(3). Recent physical evidence supports the co-
occurrence of both H3K4me3 and H3K27me3 on the same nucleosomes, and demonstrates 
resolution of bivalent domains upon differentiation(4). This leads to current understanding 
that these marks indicate genes 'poised' for response to some differentiation or selective 
stimulus.  
 
Aberrant gene silencing, leading to inactivation of tumour-suppressors and dysregulation of 
cell growth, has long been regarded an important feature of carcinogenesis(5). More 
recently, it has been shown to play an active role in the acquisition of drug resistance driven 
by epigenetic and genetic mechanisms (6-8). While a large body of work in the epigenetic 
area focuses on methylation of cytosines in DNA (CpG methylation), recent evidence also 
implicates histone modifications, particularly H3K27me3, as a means of aberrant gene 
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silencing in cancer. These two mechanisms are known to be linked(9), and genes associated 
with bivalent marks in ES cells are enriched in genes with promoter CpG hypermethylation in 
cancers(10). A further observation linking PRC2 with cancer, and particularly to cancer stem 
cells, is that the histone methyltransferase component of PRC2, EZH2, is overexpressed in 
tumour-initiating subpopulations of ovarian cancer cell lines, and inhibition of EZH2 inhibited 
tumour growth(11). High EZH2 expression has been associated with poor outcomes in a 
range of cancer types(12,13). 
 
We previously showed that a primary high-grade serous ovarian tumour had bivalent 
chromatin domains enriched for loci that are bivalently marked in ES cells, but additionally at 
loci detected only in the tumour(14). These bivalently marked genes were preferentially 
silenced in tumour-initiating subpopulations of an ovarian cancer cell line and in the 
platinum-resistant isogenic pair of a platinum-sensitive ovarian cancer cell line. This 
suggests that the acquisition of stem cell associated bivalent chromatin domains could 
provide tumour cells a mechanism for rapid adaptation to drug exposure, with expression 
changes made more persistent through acquisition of DNA methylation. The involvement of 
these epigenetic alterations in cancer cell populations may result from adaptation of normal 
cellular differentiation involved in tissue maintenance and regeneration, and could link the 
process of tumour initiation to later acquired drug resistance(15). It is therefore relevant that 
a definitive stem cell populations from both ovarian and fallopian tube epithelia have recently 
been characterized(16). 
 
We have now generated histone modification profiles from further primary high-grade serous 
ovarian tumours and from normal ovarian tissue in an attempt to shed light on the role of 
bivalent chromatin domains in ovarian carcinogenesis and acquired drug resistance in 
patients. A schematic summary of our approach and our key findings are shown in Figure 1. 
As would be expected, there is variation in the sets of H3K27me3 and H3K4me3 marked 
genes from tumour to tumour. However, we show that the expanded common set of genes 
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bivalently marked in ovarian tumours is strongly enriched for the canonical PRC2 target 
genes associated with differentiation. Importantly, we use paired tumour samples taken from 
a cohort of patients before and after the acquisition of platinum resistance to show that these 
bivalently-marked PRC2 target genes are predisposed towards epigenetic silencing via gain 
of DNA methylation following chemotherapy, during acquired drug resistance of patients’ 
tumours.  
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MATERIALS AND METHODS 
 
Sample collection and cell lines 
Four high-grade serous epithelial ovarian tumour samples from untreated patients at primary 
presentation, three normal ovarian surface epithelium samples and one normal fallopian 
tube epithelium sample were approved and obtained from the ‘HTA-approved’ Imperial 
College Healthcare NHS Trust Tissue Bank (authorized by the Wales MREC). Tumour 
collection and analysis for this study was approved by the West London Research Ethics 
Committee (reference 09/H0707/89) according to Declaration of Helsinki. Written consent 
was obtained from all patients included in this study who provided tumour tissue for 
research.  
PEA1 and PEA2 cell lines (17) were obtained and used within 6 months from Department of 
Surgery and Cancer cell stocks. STR profiling was used to authenticate cell lines prior to 
freezing and to confirm that pairs of lines were related. All cell lines were mycoplasma free 
and checked fortnightly. 
Chromatin immunoprecipitation, sequencing and PCR 
All ChIP-seq sample processing and library preparation was performed as previously 
described(14). ChIP libraries were sequenced using an Illumina HiSeq2000 at the CSC 
Genomics Core Laboratory of Imperial College London. Individual 50bp reads were filtered if 
they contained 5 base calls with quality Phred score less than 30, or if they contained any 
undetermined bases. The remaining reads were mapped to the hg19 reference genome 
using Bowtie2(18). Reads were further filtered so that a maximum of one uniquely-mapped 
read was kept for each genomic co-ordinate. All reads mapping to the DAC Consensus 
Excluded Regions were discarded and cross-correlation for each filtered sequence library 
was calculated as described(19) across a range of inter-strand offsets from 1 to 200bp, at 
5bp intervals. Locations of significant peaks of enriched DNA in each of the ChIP samples 
were identified using MACS v1.4.2(20) using a p-value cutoff of 1e-4. 
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IP-enrichment of candidate regions was confirmed through qPCR of IP chromatin from the 
high-grade serous ovarian cancer cell line PEA1. Cells were crosslinked with 1% 
formaldehyde and processed according to (21). Briefly, chromatin extract were sonicated 
using a Diagenode sonicator using 20 cycles (30 s on and 30 s off) at maximum intensity. 
Purified chromatin was then immunoprecipitated using 4 μg of H3K4me3 (Abcam 8580) or 
H3K27me3 (Abcam 6002) antibodies per ChIP. Non-immunoprecipitated chromatin was 
used as Input control. PCR primer sequences are given in Supplementary Table S1. IP 
enrichment was calculated as 
𝑖𝑛𝑝𝑢𝑡_𝐷𝑁𝐴𝑐𝑜𝑛𝑐
𝐶ℎ𝐼𝑃_𝐷𝑁𝐴𝑐𝑜𝑛𝑐
2−∆𝐶𝑡, where ∆𝐶𝑡 denotes the difference in 
amplification Ct values between input DNA and antibody pull-down DNA. 
 
Assessing differential methylation and expression in clinical samples 
All DNA methylation data was taken from ovarian tumour and ascites samples from the 
ICGC study(22) profiled on the Illumina 450k HumanMethylation arrays. 11 paired primary-
relapse samples were available from which the primary sample was tumour but the paired 
relapse sample was from ascites, and 1 pair where tumour material from relapse was also 
obtained. In addition, 3 pairs of tumour and ascites samples both taken at primary 
presentation were available.  To account for tissue-specific methylation differences between 
tumour cells and ascites, differential methylation was evaluated in terms of the fold-increase 
in methylation M-values between primary and relapse samples for each pair, divided by the 
average fold-increase in methylation M-values between tumour and ascites pairs. For 
differential gene expression, log-transformed, normalized FPKM RNA-seq counts were 
obtained for each gene from the ICGC ovarian cancer study(22). Statistics for differential 
expression were calculated using LIMMA(23) with a linear model term for each patient, a 
term to model tissue-specific differences and a term to model differences from primary to 
relapse. Empirical Bayes moderated t-statistics were obtained for the primary-vs-relapse 
coefficient for each gene. 
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Bisulphite Pyrosequencing 
A total amount of 500 ng of genomic DNA was bisulphite modified using the Zymo Research 
EZ-DNA Methylation Kit (Cambridge Bioscience) according to the manufacturer's 
instructions. Sequences of pyrosequencing primer sets are provided in Supplementary Table 
S1. Pyrosequencing PCR was performed in duplicate for each sample in a 25 μl volume 
containing an end-concentration of 1 U Faststart Taq polymerase (Roche, Welwyn Garden 
City, UK), 1x FastStart PCR Buffer including 2 µM MgCl2 (Roche), 0.05 mm dNTPs (Roche), 
0.4 µM primers (each) adding 1 μl of modified DNA template using the following conditions: 
95 °C for 6 min, 45 cycles of 95 °C for 30 s, 58 °C for 30 s, 72 °C for 30 s, followed by 72 °C 
for 5 min and terminating at 4°C. Pyrosequencing of PCR products was performed on 
PyroMark Q 96 MD using the PyroGold Reagent Kit (Qiagen) according to the 
manufacturer's instructions. The methylation percentage of CpG sites for individual genes 
was calculated by using the Pyro Q-CpG software (version 1.0.9), Biotage (Uppsala, 
Sweden). 
 
Statistical analysis 
Hypergeometric test refers to use of the hypergeometric distribution in R to calculate the 
probability of at least as great an observed overlap between two sets of genes occurring 
purely by chance. 
Pearson Correlation Coefficients and their corresponding significance estimates were 
calculated in R. 
The ‘GeneSetTest’ function in the Limma package(23) from Bioconductor was used to 
evaluate the statistical significance of a systematic shift of a set of genes towards an 
increase (or decrease) in measurements between two groups of samples measured in a 
molecular profiling experiment. 
Module Maps(24) were used to create signature scores for each sample, summarizing the 
level of gene expression or DNA methylation across a set of genes or CpG loci, respectively. 
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Functional annotation of poised, hypermethylated genes was carried out using DAVID 
according to described protocol(25). 
Assessment of statistical significance of observed increase in DNA methylation estimates 
from pyrosequencing of PEA1 and PEA2 cell lines was performed using the binomial 
distribution implemented in R, with null hypothesis based on an assumed probability of 0.5 of 
each locus showing higher methylation in PEA2 than PEA1. 
 
Availability of data and material 
ChIP-seq data for 4 primary tumour samples and 4 normal tissue samples, along with 
microarray data from 4 primary tumour samples, will be made available through Gene 
Expression Omnibus (GSE107931). RNA-seq and DNA methylation data from ICGC ovarian 
cancer patients at primary presentation and relapse are available from the ICGC Data Portal 
(https://icgc.org/icgc/cgp/67/304/809). All processed datasets, annotation resources and data 
analysis code will be made available for public access on the first author’s Imperial College 
website (http://www.imperial.ac.uk/people/e.curry). 
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RESULTS 
 
Bivalent chromatin marks in primary ovarian tumours associate with gene silencing 
Chromatin was extracted from 4 primary High Grade Serous Ovarian tumours, 3 healthy 
ovarian surface epithelium samples and 1 fallopian tube epithelium sample. Following 
extraction, Chromatin Immunoprecipitation (IP) in conjunction with high-throughput 
sequencing (ChIP-seq) was performed (as described in materials and methods) to identify 
genome-wide positioning of the permissive histone mark H3K4me3 and the repressive mark 
H3K27me3. Regions of significant enrichment of IP over input DNA control, referred to as 
'peaks,' were computed for each sample and each histone mark using MACS(20). Genes 
with peaks in both active and repressive histone marks lying within 2kb of their TSS were 
called bivalently-marked. All samples showed evidence of bivalent promoters, with all tumour 
samples showing significantly more genes carrying bivalent marks than would be expected 
from random overlap of the individual active and repressive marks (see Supplementary 
Information). The number of bivalently marked genes in each sample is markedly correlated 
(Pearson Correlation Coefficient 0.856, p=0.0067) to the number of genes marked with 
H3K27me3 in each sample, but not H3K4me3. That is, samples with more bivalently-marked 
genes tend to have more H3K27me3-marked genes, but not more H3K4me3-marked genes, 
than samples with fewer bivalently-marked genes. This suggests that the H3K27me3 mark is 
more critical in creating the bivalent chromatin state, supporting the well-established links 
between PRC2 and repression of gene expression at bivalent promoters. It also suggests 
that the set of bivalently-marked genes in each profiled tissue is only a subsample of the full 
complement that could have been observed. This motivated us to identify regions of the 
genome that show a disposition toward bivalency across multiple tumours but not in the 
normal tissue samples. 
 
Combining this with the set of bivalently marked genes from a previous experiment(14) gave 
us a list of  genes with evidence for poised promoter chromatin states in multiple primary 
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high-grade serous ovarian tumours, but not in normal ovarian surface or fallopian epithelia 
(provided in Supplementary Table S2). 
 
Previous work showed that genes with bivalent promoters were more likely to be 
transcriptionally silenced in the profiled tumour than genes with active promoter marks(14). 
Applying the same analysis strategy to gene expression microarray data obtained from the 
tumours that were used for ChIP-seq profiling of bivalent chromatin, the average proportion 
of present, marginal and absent detection calls for all probe-sets mapping to bivalently-
marked genes were compared against the proportions for probe-sets mapping to genes with 
H3K4me3 mark only. Genes with bivalently-marked promoters were significantly less likely to 
be expressed at a detectable level (Chi-squared test p<2.2e-16), suggesting that the set of 
bivalently-marked genes are representative of a degree of functional epigenetic silencing. 
 
Poised genes in primary tumours are enriched for regulators of cell fate 
Genes marked with bivalent promoters in ES cells are considered to be key determinants of 
differentiation  pathways, being in a poised state that retains the capacity to either increase 
or decrease transcription rates rapidly when required. The genes harbouring proximal 
bivalent chromatin domains in the ovarian tumours analysed are highly enriched for 
Polycomb targets with poised promoters in ES cells (Hypergeometric test p=5.8e-100, PRC2 
targets obtained from (26)). Although the cell of origin of serous ovarian cancers remains 
contentious with both ovarian surface and fallopian tube epithelia being suggested(27,28), a 
recent study provided molecular characterization of a definitive ovarian and fallopian tube 
epithelial stem cell population in the mouse, marked by expression of Lgr5(16). The set of 
genes with bivalently-marked chromatin in the ovarian tumour samples was significantly 
enriched for human orthologs of genes that were downregulated in the Lgr5+ stem cell 
compartment relative to Lgr5- comparison (Hypergeometric test p= 0.006). As there was no 
such enrichment for orthologs of the genes upregulated in Lgr5+ cells, it would appear that 
repression of transcription of genes marked with bivalent chromatin in ovarian tumour cells 
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would keep the cells in a more 'stem-cell like' state, but maintaining the capacity to lose stem 
cell associated features rapidly as and when required. Table 1 displays a summary of the 
numbers of genes in each set. 
 
Bivalent chromatin domains and DNA hypermethylation during acquisition of drug resistance 
To examine the hypothesis that bivalent promoters in tumours at presentation may 
predispose genes towards hypermethylation during acquisition of drug resistance, we have 
integrated our ChIPseq data with RNA expression and DNA methylation data generated by 
the International Cancer Genome Consortium (ICGC) of high grade serous ovarian cancer, 
including paired samples from patients both at primary, chemo-naïve, presentation and upon 
relapse following platinum-based chemotherapy(22). It has previously been shown that key 
differentiation genes bivalently marked with promoters in ES cells are predisposed toward 
hypermethylation during tumour development(10,29). Consistent with this, the set of 
promoters we identify that have hypermethylation in primary tumours relative to normal 
fallopian tube tissue samples show enrichment for ES Polycomb target genes (Limma Gene 
Set Test p=0.01). Further, we see an enrichment of the ES Polycomb targets among the set 
of genes which gain promoter CpG methylation at drug-resistant relapse compared to 
primary chemo-naïve tumours (Hypergeometric test p=2.1e-08). These ES Polycomb target 
genes also show a systematic downregulation of gene expression from primary to relapse 
samples (Limma Gene Set Test p=6.0e-10). Genes with proximal CpG loci gaining 
methylation, compared to all genes, show a significant systematic downregulation of gene 
expression from primary to relapse samples (Limma Gene Set Test p=3.5e-05), arguing that 
the gain of DNA methylation is associated with the reduction in expression. 
 
To evaluate systematic changes of promoter CpG methylation following chemotherapy 
across genes marked with bivalent chromatin domains in primary, chemo-naïve, ovarian 
tumour cells, we calculated the average change in CpG methylation between matched 
primary and relapse samples from the same patient. Comparing the corresponding 
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distribution for loci in bivalently-marked promoters with that of all promoter CpGs, we see a 
systematic shift towards greater hypermethylation (t-test p=0.036, Supplementary Figure 
S1). We computed Module Map scores(24) to summarize promoter CpG methylation across 
entire gene sets in each sample for illustration in the heatmap in Figure 2A, with average 
module map scores across primary and relapse samples shown in Figure 2B. To further 
demonstrate that this effect was due to more hypermethylation and not less 
hypomethylation, we extracted only those loci with greater than 2-fold average increase in 
methylation in relapse samples compared to primary tumours (given in Supplementary Table 
S3), and found that this set was enriched for the set of promoters with bivalent chromatin 
domains identified by ChIPseq in primary ovarian tumours (Hypergeometric test p=0.004). 
Functional annotation of the list of genes that are both bivalently marked and show at least 
2-fold increase in DNA methylation upon relapse suggests a link between this 
hypermethylation and a suppression of cellular differentiation (GO terms ‘pattern 
specification process’ and ‘cell fate commitment’ were enriched with adjusted p-values 7.2e-
8 and 1.9e-4, respectively, a full table of enriched GO terms is provided in Supplementary 
Table S4). Some of the samples are observed to have clearer systematic promoter 
hypermethylation of these target genes than others. In fact there is considerable 
heterogeneity, both within the primary and the relapse tumours, in the levels of DNA 
methylation for even the gene set representing the most consistently differentially-
methylated between the groups. This may arise from multiple alternative mechanisms for 
silencing being employed in the tumours, as found in (30). 
 
In primary tumour and relapse pairs taken from the ICGC patient cohort (n=10), gene 
expression profiling by RNA-seq data shows a systematic down-regulation of the set of 
genes marked with bivalent chromatin domains in primary ovarian tumour cells (Limma 
Gene Set Test p=0.037). We computed Module Map scores to summarize expression levels 
across entire gene sets in each sample for illustration in the heatmap in Figure 2C, with 
average module map scores across primary and relapse samples shown in Figure 2D. 
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Interestingly we also see that the orthologs of Lgr5-downregulated genes in the mouse 
ovarian stem cell model show a strong systematic down-regulation of expression in relapsed 
samples relative to primary tumours (Limma Gene Set Test p<1e-12). This latter observation 
implies that tumour cells upon relapse have a more stem-cell-like gene expression profile 
and that bivalent chromatin marks may provide a mechanism for the observation that high 
grade serous ovarian cancer cells enhance stem cell like characteristics following exposure 
to chemotherapy(10) (11). The individual PRC2 complex members EZH2, EED and SUZ12 
all showed higher median expression in the relapse samples relative to primary samples, but 
this difference was only statistically significant in the case of SUZ12 (paired t-test p=0.025). 
Further, we saw significant overexpression of DNMT3B (p=0.047), which suggests that 
transcriptional upregulation of this de novo DNA methyltransferase may be involved 
mechanistically in the observed epigenetic silencing of bivalently-marked genes. 
 
We computed the difference in average promoter methylation and the difference in 
expression for each gene in each pair of primary-relapse samples. These differences were 
negatively correlated (Pearson correlation -0.05, product-moment test p=0.002), indicating 
increases in promoter methylation tending associating with decreases in expression. The set 
of bivalently marked genes showed on average a greater increase in methylation and 
greater decrease in expression between primary and relapse samples than other genes (t-
test p=0.09 and p=0.08, respectively). The absolute promoter methylation levels of bivalent 
genes were similarly distributed to those of all other genes, but with more frequent 
occurrence of methylation >10% (Supplementary Figure S2). This relationship was observed 
in both primary and relapse samples. 
 
To suggest key pathways affected by the epigenetic change during chemotherapy and 
relapse, we computed the average change in promoter methylation and gene expression 
across all bivalently-marked genes in pathways from the Consensus Pathway Database 
(31), from primary to relapse samples. A significant negative correlation was observed at the 
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pathway level between change in methylation and change in expression (Pearson 
correlation coefficient -0.2, p<2x10-16). We noted systematic increases in methylation and 
decreases in expression of genes in ‘BMP signalling’ and ‘MicroRNAs in cancer’ pathways 
(Supplementary Figure S3). miRNA signalling has previously been demonstrated to be 
regulated through DNA methylation (32) and implicated in drug resistance (33) in ovarian 
cancer. BMP signalling is known to regulate differentiation (34), and less differentiated stem 
cells are known to be more resistant to chemotherapy (35). These observations therefore 
suggest possible mechanisms relating to the acquired drug resistance observed in these 
relapsed tumours. 
 
A set of candidate loci from the bivalently-marked genes showing hypermethylation on 
relapse were selected for independent evaluation in the PEA1/PEA2 isogenic cell line pair 
(17). Bivalent marks at promoters for DXL5, TRIM7, CYP21B1 and HOXD10 in the primary 
tumour derived cell line PEA1 were confirmed through ChIP-qPCR. Fold-enrichment from IP 
with antibodies targeting each of H3K4me3 and H3K27me3, relative to input DNA, is shown 
in Figure 3A. All selected loci show marked enrichment of the target regions through both 
H3K4me3 and H3K27me3 ChIP. Levels of DNA methylation for CpG sites in these promoters 
were assayed through bisulphite pyrosequencing, in both primary tumour derived cell line 
PEA1 and the cell line PEA2, which was derived from the same patient as PEA1 but after 
chemotherapy and subsequent relapse (17). Methylation levels (an average of 3 replicates) 
for these CpG sites are presented in Figure 3B, showing an increase in methylation in PEA2 
relative to PEA1 for 11 of the 14 loci. Assuming under randomness that each CpG site would 
have a 50% chance of being measured at a higher level in PEA2 relative to PEA1, we have 
p=0.02 for seeing at least that many loci hypermethylated in PEA2 purely by chance. Of the 
4 genes tested, only TRIM7 didn’t feature at least 1 CpG site with >10% increase in 
methylation. This independent evaluation supports the systematic promoter 
hypermethylation of bivalently-marked genes that we established based on analysis of 
patient samples. To relate changes in DNA methylation to changes in gene expression, we 
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mapped RNA-seq reads from the PEA1 and PEA2 cell lines to these candidate genes and 
normalized to the number of reads mapping to GAPDH in each replicate (co-ordinates and 
counts given in Supplementary Table S5). Figure 3C shows 3 of the 4 genes markedly down-
regulated in PEA2, and a systematic decrease across the entire bivalently marked gene set 
(Wilcoxon signed rank test p<2x10-16) is observed, confirming a general trend for silencing of 
these genes following exposure to chemotherapy. 
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DISCUSSION 
 
We previously proposed a model in which overexpression of EZH2 in cancer cells, 
particularly those with lower proliferation rate and greater tumorigenic capacity, leads to 
aberrant marking of promoters with bivalent chromatin domains, predisposing these loci to 
epigenetic silencing via DNA methylation during the course of tumour evolution towards an 
acquired drug resistant state(15). We previously presented evidence of bivalent chromatin 
domains in a primary ovarian tumour, showed that these were enriched for Polycomb targets 
associated with developmental regulation, and linked the bivalently marked genes to 
transcriptional silencing in tumour-initiating cell enriched subpopulations and chemotherapy-
resistant models of ovarian cancer cell lines(14). However, access to paired tissue samples 
from patients prior to and after exposure to chemotherapy in our present study allowed us to 
demonstrate systematic epigenetic silencing of bivalently marked gene sets occurring in 
patients in the course of treatment. During this time, the cancer cells have been exposed to 
platinum-based chemotherapy and have both regrown a tumour mass and altered their drug 
sensitivity so that the same cytotoxic chemotherapy is less effective at therapeutic doses. 
While genetic change such as reversion of Brca1 mutations are important in drug resistance 
and treatment failure at relapse, epigenetic change such as DNA methylation also has a key 
role (6,36). We observe bivalent genes defined from primary HGSOC tumours compared 
against normal ovarian and tubal epithelia, and to canonical Polycomb targets defined in ES 
cells, which gives assurance that the gene sets analysed are not overly dependent on data 
from individual subjects. Given that we see lower expression of Lgr5-downregulated 
orthologs in relapse tissue, and functional annotation of the genes found to be bivalently-
marked and hypermethylated upon release points to a signature associated with cell fate 
specification, we believe that epigenetic reprogramming associated with drug resistant 
relapse could reflect a more stem-like phenotype through suppression of differentiation. 
Alternatively, it may be that stem cells and tumour cells share common mechanisms of 
poised chromatin states. Thus cancer cells may also be using the regulation of poised 
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chromatin states to flexibly respond to selective pressures allowing increased plasticity.  It 
can be seen that there is variability in the extent of hypermethylation of these gene sets, with 
some patients showing greater increases in methylation between primary and relapse than 
others. This cohort is too small to consider whether there are clinical implications of the 
extent of hypermethylation of bivalently marked genes, but this would be interesting to 
investigate should methylation profiles be obtained from more paired samples. 
 
With available data we cannot differentiate between poised states leading to the acquisition 
of silencing during chemotherapy, as opposed to bivalently marked loci already being fully 
silenced in (drug-resistant) clones within the primary tumour sample which survived and 
grew out following initial treatment to form the relapse. The only way to address this 
definitively would be to use single-cell genetic and epigenetic profiling of all tumour samples, 
which remains technically infeasible at this time. It also remains to be demonstrated whether 
or not any of the epigenetic silencing events we have observed are directly contributing to 
the functional acquisition of drug resistance in high grade serous ovarian cancer cells, 
although our set of genes with bivalent promoters in tumours included FLNC and MDK, 
previously identified key drivers of epigenetically-mediated acquisition of drug resistance in 
ovarian tumour cell line models(6). Proof of a direct causal link would require further 
experimental evidence. Such experiments would require emergence of epigenetic editing 
technology (e.g. (37)) to induce the presence or absence of bivalent marks at PRC2 target 
gene promoters, then follow an appropriate model through acquisition of drug resistance, 
monitoring changes to DNA methylation and gene expression. As such technology is still in 
development, experimental proof of causality is beyond the scope of this study. 
 
Importantly, we have shown that the histone modification profile from a primary tumour at 
initial clinical presentation is informative of the DNA methylation and gene expression state 
of drug-resistant tumour at relapse many months after treatment.  This suggests that drug-
resistant disease could theoretically be targeted before it develops, through a personalized 
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medicine strategy that utilizes epigenetic profiles obtained from a primary tumour sample to 
predict the most likely drivers of subsequent resistance. One can imagine a situation in 
which the bivalent chromatin profile of a tumour is mapped and used to select, from a list of 
available therapeutics targeting genes or pathways known to cause chemotherapy 
resistance, those with targets most likely to become altered during disease relapse. 
Alternatively, it may be the case that the epigenetic silencing events are acquired during 
chemotherapy and only in a poised state at presentation, a scenario that might be implied by 
the observation of overexpression of the PRC2 complex member SUZ12 and the de novo 
DNA methyltransferase DNMT3B on drug-resistant relapse. The emergence of 
chemotherapy resistance is facilitated by the ability of cancer cells to alter their epigenetic 
landscape, particularly via controlling bivalent chromatin domains and DNA methylation. 
Treating patients with drugs that target these processes, either along with chemotherapy or 
in a maintenance setting during remission, could prevent the cancer cells from adapting their 
epigenetic landscape to acquire chemotherapy resistance. 
 
We have shown here that ovarian tumour cells harbour the bivalent chromatin domains that 
are characteristic of pluripotent cells held in an undifferentiated state poised to undergo rapid 
phenotypic change on lineage commitment. Specifically, we see poised chromatin states 
leading to epigenetic silencing of genes involved in stem cell differentiation, implying this 
disruption of normal differentiation processes as a potential mechanism by which tumour 
cells could adapt to the presence of cytotoxic chemotherapy and that common mechanisms 
give rise to drug resistant populations as observed during normal cell differentiation. 
Promoters kept in a poised state by the presence of these domains would enable cells not 
immediately killed by cytotoxic chemotherapy to adapt to the changes in their environment 
brought about by this treatment, and repopulate a tumour with cells re-programmed to 
suppress cellular mechanisms of drug sensitivity and treatment response.  While we observe 
these similarities of ovarian cancer cells to ovarian stem cells, we do not have data to 
assess the extent to which cancer cells derive from stem cells. It would be possible for these 
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cells to use alternative mechanisms of establishing and maintaining bivalent chromatin 
domains, and that these could be located in different positions throughout the genome. 
Lineage tracing experiments to investigate tumour formation from Lgr5-expressing cells 
would be of interest to us but beyond the scope of this study. In this context we highlight the 
observation that mouse Lgr5+ stem cells of the ovary and fallopian tube overexpress Ezh2 
relative to the Lgr5- differentiated ovarian and tubal epithelia(16). Tumour-initiating 
subpopulations of human cancer cell lines with stem cell-like properties also overexpress 
EZH2 relative to non-tumour initiating subpopulations(11). If both the normal adult stem cell 
compartment of the ovary and tumour initiating cells of ovarian cancers overexpress the 
enzyme responsible for deposition of the H3K27me3 histone mark, which is a key step in 
formation of bivalent chromatin domains, it may suggest that this mechanism is already 
present in the normal physiology of the ovary. This, in turn, would indicate that high grade 
serous ovarian cancers are physiologically disposed towards this capacity for epigenetically 
driven acquired drug resistance. We speculate that therapeutics targeting aberrant PRC2 
activity in tumour cells during remission, such as histone methyltransferase inhibitors, could 
prevent acquisition of resistance by DNA methylation to widely-used cytotoxic 
chemotherapies and offer a means of preventing drug resistance emergence. 
 
In conclusion, we have shown that high grade serous ovarian cancer at initial presentation 
have bivalently marked chromatin domains, containing active H3K4me3 and repressive 
H3K27me3 histone marks, which define gene sets that are more likely to have increased 
promoter CpG methylation and reduced gene expression at patient relapse with resistant 
disease. This provides the first evidence from patient samples that epigenetic silencing 
during acquired drug resistance could be underpinned by pre-existing histone modifications 
associated with genes being in a poised state.  
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TABLES 
Table 1: Summary of numbers of genes with bivalent marks in ovarian tumour and 
normal tissues 
Tissue Source Bivalently Marked 
Genes  
ES Polycomb 
Targetsa 
(out of 1567) 
Ovarian Lgr5 
Targetsb 
(out of 203) 
Ovarian Tumour 747 217 11 
Normal (OSE, 
FT) 
207 23 3 
a. Previously described Polycomb targets in ES cells(26) 
b. Orthologs of genes downregulated in Lgr5+ mouse ovary cells(16). 
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FIGURE LEGENDS 
 
Figure 1 – Graphical Summary of Analytical Approach and Key Findings 
ChIP-seq for H3K27me3 and H3K4me3 (in comparison to input DNA) was used to obtain 
genome-wide bivalent mark profiles in 4 primary ovarian tumours and 4 normal tissue 
samples, supplemented by the profile from a primary ovarian tumour obtained from our 
previous study. Genes with both H3K27me3 and H3K4me3 marks within 2kb of the TSS in 
any of the tumours but none of the normal tissues were taken forward as representative of 
poised genes in primary ovarian cancers. These genes systematically gained methylation 
and reduced expression in ovarian cancer patient samples obtained at relapse following 
cytotoxic chemotherapy treatment, relative to their primary tumour samples. The set of 
genes which were both poised in primary tumours and epigenetically silenced upon relapse 
were strongly enriched for regulators of differentiation, including the classical ES cell 
Polycomb targets. 
 
Figure 2 – Module Maps Summarizing DNA Methylation and Gene Expression 
Signatures 
Heatmaps show module map scores for gene sets in terms of DNA methylation (A) and gene 
expression (C) in individual primary tumour and relapse ascites samples from the ICGC 
high-grade serous ovarian cancer cohort. DNA methylation module map scores log2-
transformed in (A). Set of genes with bivalent chromatin domains in ovarian tumours is 
labelled ‘tumour.bivalent’, set of polycomb targets in ES cells is labelled ‘prc2’, set of 
orthologs of genes repressed in Lgr5+ mouse ovary stem cells is labelled ‘lgr5.targets’, sets 
of genes up- and down-regulated in expression in relapse ascites relative to primary tumours 
are labelled ‘relapse.hi’ and ‘relapse.lo’ respectively, and sets of genes hyper- and hypo-
methylated in relapse ascites relative to primary tumours are labelled ‘relapse.hyper’ and 
‘relapse.hypo’ respectively. Colour bar along top of the heatmaps indicates primary samples 
with blue and relapse samples with pink. Average module map scores across all primary 
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samples (blue) and all relapse samples (pink) are shown in bar charts (B) for DNA 
methylation and (D) for gene expression. These show that methylation tends to increase in 
relapse for the genes with bivalent marks in primary ovarian tumours, for the polycomb 
targets in ES cells and for genes decreasing expression on relapse. Methylation tends to 
decrease in relapse for the genes increasing expression on relapse. Gene expression shows 
the opposite trend, decreasing for the genes with bivalent marks in primary ovarian tumours 
and for the polycomb targets in ES cells. 
 
Figure 3 – Evaluation of bivalent chromatin marks and hypermethylation in 
PEA1/PEA2 ovarian cancer cell line model 
(A) Fold-enrichment from H3K4me3 and H3K27me3 immunoprecipitation of PEA1 cell line 
DNA at promoter regions of candidate genes, based on ChIP-qPCR quantification. Each IP 
shown is an average of two independent chromatin extractions, pull-down and amplification. 
Values shown reflect concentration of target region DNA relative to all DNA in the sample, 
normalized to no-IP input DNA. (B) Quantification of promoter CpG methylation levels in 
PEA1 and PEA2 cell lines by bisulphite pyrosequencing. Values shown represent proportion 
of sequenced DNA fragments with the corresponding CpG site methylated, out of all 
sequenced DNA fragments mapping to that CpG site. Each assay reflects the average of 3 
independent DNA extractions. (C) Quantification of gene expression levels in PEA1 and 
PEA2 cell lines from RNA-seq. Values shown represent number of reads mapped to each 
gene relative to number of reads mapping to GAPDH, in each of 3 replicates. 
 



